Finance

Lists
Q3 2026 earnings • released • EPS beat +14.91% • Revenue beat +2.70%
See results
BMYB34:BVMF
Bristol-Myers Squibb Company BDR
R$323.91
0.00%
(0.00) 1D
Oct 29, 4:56:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BMYB34...
Open
R$323.52
High
R$323.91
Low
R$323.52
Mkt. cap
125.40B
Avg. vol.
10.00
Volume
6.00
52-wk high
R$347.15
52-wk low
R$221.72
Shares outstanding
2.04B
No. of employees
32K
Open
R$323.52
High
R$323.91
Low
R$323.52
Mkt. cap
125.40B
Avg. vol.
10.00
Volume
6.00
52-wk high
R$347.15
52-wk low
R$221.72
Shares outstanding
2.04B
No. of employees
32K
News stories
From web sources and news partners
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com
Last report
Oct 29, 2026
Fiscal period
Q3 2026
$1.35 / $1.17
+14.91%beat
Revenue / Est. (USD)
13.07B / 12.73B
+2.70%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
12.22B
12.50B
11.49B
12.97B
Cost of goods sold
3.31B
3.51B
3.41B
3.71B
Cost of revenue
3.31B
3.51B
3.41B
3.71B
Research and development expenses
2.43B
2.56B
2.24B
2.54B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.79B
2.09B
1.61B
1.82B
Operating expense
5.05B
5.47B
4.28B
4.80B
Total operating expenses
8.36B
8.98B
7.69B
8.51B
Operating income
3.86B
3.52B
3.80B
4.46B
Other non operating income
529.00M
544.00M
125.00M
106.00M
EBT including unusual items
3.11B
1.47B
3.24B
4.09B
EBT excluding unusual items
4.07B
3.86B
3.65B
4.35B
Income tax expense
919.00M
384.00M
561.00M
770.00M
Effective tax rate
29.51%
26.12%
17.32%
18.84%
Other operating expenses
-
-
-
-
Net income
2.20B
1.09B
2.68B
3.32B
Net profit margin
18.01%
8.69%
23.30%
25.57%
Earnings per share
1.63
1.26
1.58
2.04
Interest and investment income
161.00M
148.00M
104.00M
101.00M
Interest expense
-482.00M
-432.00M
-406.00M
-403.00M
Net interest expenses
-321.00M
-284.00M
-302.00M
-302.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.91B
4.54B
4.41B
5.08B
Gain or loss from assets sale
-9.00M
-
-34.00M
-142.00M
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps